What Дифлюзол Treats: Main Uses and Benefits

Дифлюзол is primarily used to manage a wide range of fungal infections caused by susceptible yeasts. The core benefit is to provide therapeutic support for managing these infections across various clinical scenarios.

Common uses include addressing vaginal candidiasis (yeast infection), oropharyngeal and esophageal candidiasis (thrush), and systemic infections like cryptococcal meningitis and candidemia (fungal blood infection). The medicine is used to provide timely symptom relief, helping to lessen the itching, burning, and pain associated with these conditions, which contributes to improved functional comfort.

---

“The primary goal of therapy is to help manage symptoms and promote functional improvement.”

---

The use of this medicine aligns with established therapeutic guidelines for managing these conditions. The medicine is a systemic option used to address the infection, particularly for patients who may be at high risk for recurrence.

---

Quick Fact: Relief for Persistent Itching

Дифлюзол, whose active ingredient is fluconazole, is an antifungal medication generally safe for use in most adults and children, often prescribed for serious fungal or yeast infections. For specific populations, its use requires careful medical consideration or is contraindicated.

---

Who Can Use Дифлюзол?

Group	Consideration
Adults and Adolescents (usually 16 years and older)	Commonly used for various fungal infections, including vaginal thrush.
Children (aged 6 months to 15 years)	Appropriate studies have shown safety and efficacy for many infections, but the dose must be determined by a doctor based on body weight.
Elderly	Generally safe, but kidney function should be monitored as age-related changes may require dose adjustment.

---

Who Should NOT Use Дифлюзол?

Fluconazole is contraindicated if you have a known allergy to fluconazole, other azole antifungals (like ketoconazole), or any of its inactive ingredients. It should also not be taken with certain medicines that prolong the QT interval and are metabolized by the CYP3A4 enzyme, such as terfenadine, astemizole, cisapride, pimozide, or quinidine, due to the risk of serious heart rhythm problems.

Caution is required if you have pre-existing conditions, including kidney disease, liver disease, heart conditions (especially heart rhythm problems or QT prolongation), or electrolyte imbalances (like low potassium). Pregnancy should be avoided during and for one week after treatment. High-dose, long-term use in the first trimester has been associated with rare birth defects. If you are pregnant or breastfeeding, discuss the risks and benefits with your doctor.

The official regulatory documents define the interaction profile of Дифлюзол (Fluconazole) primarily through its effect as a systemic inhibitor of Cytochrome P450 enzymes. Fluconazole is documented as a potent inhibitor of CYP2C9 and CYP2C19, and a moderate inhibitor of CYP3A4. This metabolic action leads to a clinically significant pharmacokinetic interaction that increases the plasma concentration and systemic exposure of numerous co-administered medicines that rely on these enzymes for clearance.

The official label lists specific substances whose exposure is increased, including the anticoagulant Warfarin, the anticonvulsant Phenytoin, certain oral contraceptives like Ethinyl Estradiol, and immunosuppressants like Cyclosporine. Regulatory constraints classify the combination of Fluconazole with several agents as formally contraindicated due to the risk of severe pharmacodynamic interactions, notably QT interval prolongation; these prohibited medicines include Pimozide and Quinidine.

Fluconazole’s own exposure is also subject to documented interactions. The diuretic Hydrochlorothiazide causes a documented increase in Fluconazole’s AUC due to reduced renal clearance, while the inducer Rifampicin reduces Fluconazole exposure. The official profile also notes that systemic exposure is higher in the elderly population. Regarding non-medicinal substances, the regulatory profile confirms that the drug’s oral absorption is not affected by food intake, allowing administration without regard to meals.

How Дифлюзол Works

Дифлюзол's active ingredient, Fluconazole, exerts its effect by interfering solely with the fungal cell's metabolic processes. The drug acts as an inhibitor of the enzyme cytochrome P450-dependent 14alpha-lanosterol demethylase (14alpha-demethylase), which is vital for synthesizing ergosterol, the primary sterol of the fungal cell membrane.

Blocking 14alpha-demethylase prevents the production of functional ergosterol while simultaneously causing a toxic buildup of 14alpha-methyl sterols within the cell. These precursor sterols integrate into the fungal membrane, dramatically increasing its permeability and leading to structural failure. This molecular disruption halts the fungal cells' ability to grow and multiply, defining the medication's mechanism as fungistatic—a physiological outcome achieved entirely by compromising the fungal cell's structural integrity and reproductive capacity.

The administration of Дифлюзол (Fluconazole) is structured around official, standardized protocols utilizing both oral (capsules, tablets, liquid) and intravenous (IV) infusion routes. The oral forms may be taken without regard to meals, as food intake does not significantly affect the drug's absorption. When a patient's route is transitioned from IV to oral, the daily dosage remains the same.

The protocol for multi-dose regimens requires a loading dose on the first day of treatment, which is typically twice the recommended daily maintenance dose to achieve therapeutic levels quickly. Following this initial dose, the medicine is generally administered once daily. Maintenance dosages range widely from 50 mg to 400 mg daily, depending on the clinical requirement, while specific acute conditions utilize a single 150 mg oral dose.

The duration of use is highly variable, ranging from a single dose up to maintenance therapy extending for six months or longer for suppressive treatment protocols. A critical procedural requirement is the mandated dose adjustment for patients with reduced kidney function. For these individuals, the dose must be reduced by 50% if their creatinine clearance is 50 mL/min or less. Additionally, the IV solution must be infused slowly, generally not exceeding 10 mL/minute, as a key constraint for proper administration.

Overview of Studies for Дифлюзол (Fluconazole)

---

Evidence for Managing Mucosal and Dermatological Candidiasis

Randomized Controlled Trials (RCTs) and systematic reviews have examined the use of Fluconazole for common infections like oral thrush (Oropharyngeal Candidiasis) and vaginal yeast infections. Research explored its use in populations of adults and adolescents, particularly those who are immunocompromised. Studies monitored outcomes related to physical discomfort and described patterns observed in the time it took for changes in symptoms to be measured, which researchers refer to as the clinical cure rate. Research describes reports on the rate at which certain fungal species demonstrated reduced susceptibility to the drug in highly exposed populations.

Evidence for Preventing and Treating Systemic Fungal Infections

Research has detailed the evidence base for more serious, deep-seated infections such as Candidemia (fungal blood infection) and the management of Cryptococcal Meningitis. The drug was evaluated in studies focusing on episodes where symptoms become more noticeable, such as in patients with low white blood cell counts (neutropenia). Studies reported measurements of the frequency of Invasive Fungal Infection (IFI) diagnoses in the treated group compared to the control group during the high-risk period.

For severe infections like Cryptococcal Meningitis, the drug was studied as part of a multi-stage regimen. Findings indicate patterns related to the observed rate of relapse or recurrence of the meningitis over several months of follow-up. However, evidence quality varies across studies, and findings were mixed concerning the influence of prophylactic use on overall patient survival in certain high-risk groups.

---

Key Research Gaps and Remaining Uncertainties

Research provides insight into short-term changes, but the evidence for long-term outcomes and the durability of the observed patterns is limited. Long-term effects are not fully established, particularly regarding the duration of observed stability in patients whose immune function has improved. Furthermore, while the drug was used in studies that measured outcomes in specific populations, certainty remains low regarding the ideal duration of use for prophylaxis in the neonatal population. The evidence is still emerging concerning how widespread use may influence the development of resistance in various fungal species over time, which continues to be closely monitored by researchers. The results apply only to the specific populations studied in the research.

Key Studies & References

1. Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America (IDSA)

Common questions about Дифлюзол (FAQ)

---

Q: What should I do if I overdose on Дифлюзол?

Official regulatory documents indicate that if an overdose is suspected, it is advised to immediately contact a poison control center or seek emergency medical attention. Symptoms that have been documented in regulatory reports following an overdose include changes in mental status, such as feelings of fearfulness or suspiciousness, and hallucinations (seeing, hearing, or feeling things that are not there).

---

Q: What happens if I miss a dose?

According to patient information leaflets, the recommended approach if a dose is missed is to take it as soon as it is remembered. However, if it is close to the time for the next scheduled dose, the official recommendation is to skip the missed dose and continue with the regular schedule. Product information advises against taking two doses at the same time to make up for a missed dose.

---

Q: How long does it take for Дифлюзол to start working for a vaginal yeast infection?

Studies and official product information for the single-dose formulation of Fluconazole (the active ingredient in Дифлюзол) provide information on symptom relief. Clinical studies supporting this formulation indicate that relief of associated symptoms, such as itching, burning, and discharge, typically begins within 24 hours of administration.

How to Store and Dispose of Дифлюзол (Fluconazole)

Official regulatory guidelines require all forms of fluconazole—tablets, capsules, and powder for suspension—to be stored at controlled room temperature, generally between 20°C and 25°C. The intravenous (IV) solution must be stored under the same conditions and must not be frozen. All medications must be kept out of the reach of children.

Stability and Handling

The reconstituted oral suspension is stable for 14 days when stored at temperatures between 5°C and 30°C and must be shaken well before each use. The IV solution must be visually inspected for particulate matter before administration.

Disposal

Expired or unused fluconazole should be disposed of according to local state or municipal regulations. If a drug take-back program is unavailable, follow the standard procedure of mixing the medicine with an unpalatable substance and placing it in a sealed container for household trash, as this drug is not recommended for toilet flushing.